Staar Surgical Company is a pioneering developer, manufacturer, and marketer of implantable miniature lenses, primarily used in vision correction procedures
Specializing in advanced ophthalmic technologies, the company focuses on innovative solutions for conditions such as myopia and presbyopia. Staar Surgical aims to enhance patient satisfaction and visual outcomes by providing high-quality, innovative products that are designed to improve the overall eye health and well-being of individuals seeking surgical options for improved eyesight. Through its commitment to research and development, the company continues to advance the field of vision correction and expand its global presence in the ophthalmic medical device market.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
STAAR Surgical Company (NASDAQSTAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR’s current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR’s strong relationships in the ophthalmic community.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of STAAR Surgical Company (“Staar” or “the Company”) (NASDAQSTAA) for violations of the securities laws.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
STAAR Surgical Company (NASDAQSTAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, operational progress and fiscal 2025 outlook.
STAAR SURGICAL CO was identified as a growth stock that isn't overvalued. NASDAQ:STAA is excelling in various growth indicators while maintaining a solid financial footing.
STAAR Surgical Company (NASDAQSTAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
STAAR Surgical Company (NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day.
STAAR Surgical Company (NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville, TN.
The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%).
